glp-1 anti-obesity drugs lead to substantial weight loss in the “real world” MCT2D | 2023 Updates to

And if you are eating less because the medication is doing its job suppressing appetite, you are also getting less fiber, less bulk, and less of the natural stimulation your colon needs to do its work

European regulators are already investigating whether these drugs cause users to experience suicidal thoughts

For example, a client could have $100,000 per person/$300,000 per occurrence in liability coverage

Prefilled devices also streamline administration

Canadian Medical Association Journal, 196 (43), E1413

Relative contraindications These are situations where the combination might be possible under very careful supervision but carry elevated risk that must be weighed against potential benefit: Controlled hypertension (even well-managed blood pressure requires closer monitoring on this combination) History of anxiety disorders (phentermine can exacerbate anxiety through CNS stimulation) History of pancreatitis (GLP-1 receptor agonists including tirzepatide carry a theoretical risk of pancreatitis) Gallbladder disease (rapid weight loss from combination therapy increases gallstone risk) Severe gastrointestinal conditions including gastroparesis (tirzepatide further slows already-compromised gastric motility) Kidney disease (dehydration risk from combined GI side effects can worsen renal function) If you fall into any of these categories, the conversation with your provider needs to be particularly thorough